IDO1 and TGF-β mediate protective effects of IFN-α in antigen-induced arthritis

Journal of Immunology

Volumn 197, Issue 8, 2016, Pages 3142-3151

  Chalise, Jaya Prakash ^a   Pallotta, Maria Teresa ^b   Narendra, Sudeep Chenna ^a   Carlsson, Bjorn ^a   Iacono, Alberta ^b   Namale, Joanitah ^a   Boon, Louis ^c   Grohmann, Ursula ^b   Magnusson, Mattias ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF PERUGIA   (Italy)

^c EPIRUS Biopharmaceuticals Netherlands BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; KYNURENINE; TRANSFORMING GROWTH FACTOR BETA; ALPHA BETA INTERFERON RECEPTOR; BOVINE SERUM ALBUMIN; IDO1 PROTEIN, MOUSE; IFNAR1 PROTEIN, MOUSE; INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN INDUCED ARTHRITIS; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; IDO1 GENE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TGF BETA GENE; 129 MOUSE; ANIMAL; CELL CULTURE; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; GENE EXPRESSION REGULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84991463715     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502125     Document Type: Article

References (44)

1. Garber, K. 2014. Immunology: A tolerant approach. Nature 507: 418-420.
2. Ying, F., J. P. Chalise, S. C. Narendra, and M. Magnusson. 2011. Type I IFN protects against antigen-induced arthritis. Eur. J. Immunol. 41: 1687-1695.
3. Chalise, J., S. Narendra, B. Paudyal, and M. Magnusson. 2013. Interferon alpha inhibits antigen-specific production of proinflammatory cytokines and enhances antigen-specific transforming growth factor beta production in antigen-induced arthritis. Arthritis Res. Ther. 15: R143.
4. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
5. Trinchieri, G. 2010. Type I interferon: friend or foe? J. Exp. Med. 207: 2053-2063.
6. González-Navajas, J. M., J. Lee, M. David, and E. Raz. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12: 125-135.
7. Stubgen, J. P. 2009. Recombinant interferon-beta therapy and neuromuscular disorders. J. Neuroimmunol. 212: 132-141.
8. Belladonna, M. L., C. Orabona, U. Grohmann, and P. Puccetti. 2009. TGF-βeta and kynurenines as the key to infectious tolerance. Trends Mol. Med. 15: 41-49.
9. Pallotta, M. T., C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna, R. Bianchi, G. Servillo, C. Brunacci, M. Calvitti, S. Bicciato, et al. 2011. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12: 870-878.
10. Belladonna, M. L., P. Puccetti, C. Orabona, F. Fallarino, C. Vacca, C. Volpi, S. Gizzi, M. T. Pallotta, M. C. Fioretti, and U. Grohmann. 2007. Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation 84(1, Suppl)S17-S20.
11. Belladonna, M. L., C. Volpi, R. Bianchi, C. Vacca, C. Orabona, M. T. Pallotta, L. Boon, S. Gizzi, M. C. Fioretti, U. Grohmann, and P. Puccetti. 2008. Cutting edge: Autocrine TGF-βeta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181: 5194-5198.
12. Brown, R. R., Y. Ozaki, S. P. Datta, E. C. Borden, P. M. Sondel, and D. G. Malone. 1991. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 294: 425-435.
13. Mellor, A. L., D. B. Keskin, T. Johnson, P. Chandler, and D. H. Munn. 2002. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol. 168: 3771-3776.
14. Fallarino, F., U. Grohmann, S. You, B. C. McGrath, D. R. Cavener, C. Vacca, C. Orabona, R. Bianchi, M. L. Belladonna, C. Volpi, et al. 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176: 6752-6761.
15. van den Berg, W. B., L. A. Joosten, and P. L. van Lent. 2007. Murine antigeninduced arthritis. Methods Mol. Med. 136: 243-253.
16. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
17. Matino, D., M. Gargaro, E. Santagostino, M. N. Di Minno, G. Castaman, M. Morfini, A. Rocino, M. E. Mancuso, G. Di Minno, A. Coppola, et al. 2015. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J. Clin. Invest. 125: 3766-3781.
18. Romani, L., F. Fallarino, A. De Luca, C. Montagnoli, C. D'Angelo, T. Zelante, C. Vacca, F. Bistoni, M. C. Fioretti, U. Grohmann, et al. 2008. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451: 211-215.
19. Perfetto, S. P., P. K. Chattopadhyay, and M. Roederer. 2004. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4: 648-655.
20. Munn, D. H., and A. L. Mellor. 2013. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34: 137-143.
21. Fallarino, F., U. Grohmann, and P. Puccetti. 2012. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur. J. Immunol. 42: 1932-1937.
22. Crouse, J., U. Kalinke, and A. Oxenius. 2015. Regulation of antiviral T cell responses by type I interferons. Nat. Rev. Immunol. 15: 231-242.
23. +) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collageninduced arthritis. Cell. Immunol. 278: 45-54.
24. + plasmacytoid dendritic cells. Curr. Drug Metab. 8: 209-216.
25. Chevolet, I., M. Schreuer, R. Speeckaert, B. Neyns, I. Hoorens, N. van Geel, V. Kruse, B. Hennart, D. Allorge, M. Van Gele, and L. Brochez. 2015. Systemic immune changes associated with adjuvant interferon-a2b-therapy in stage III melanoma patients: failure at the effector phase? Melanoma Res. 25: 357-361.
26. Yun, T. J., J. S. Lee, K. Machmach, D. Shim, J. Choi, Y. J. Wi, H. S. Jang, I. H. Jung, K. Kim, W. K. Yoon, et al. 2016. Indoleamine 2,3-dioxygenaseexpressing aortic plasmacytoid dendritic cells protect against atherosclerosis by induction of regulatory T cells. Cell Metab. 23: 852-866.
27. Manches, O., D. Munn, A. Fallahi, J. Lifson, L. Chaperot, J. Plumas, and N. Bhardwaj. 2008. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118: 3431-3439.
28. Manches, O., M. V. Fernandez, J. Plumas, L. Chaperot, and N. Bhardwaj. 2012. Activation of the noncanonical NF-kB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc. Natl. Acad. Sci. USA 109: 14122-14127.
29. Bailey-Bucktrout, S. L., S. C. Caulkins, G. Goings, J. A. Fischer, A. Dzionek, and S. D. Miller. 2008. Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J. Immunol. 180: 6457-6461.
30. Matysiak, M., M. Stasioek,W. Orowski, A. Jurewicz, S. Janczar, C. S. Raine, and K. Selmaj. 2008. Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J. Neuroimmunol. 193: 12-23.
31. Terness, P., T. M. Bauer, L. Röse, C. Dufter, A. Watzlik, H. Simon, and G. Opelz. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenaseexpressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196: 447-457.
32. Nguyen, N. T., T. Nakahama, D. H. Le, L. Van Son, H. H. Chu, and T. Kishimoto. 2014. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front. Immunol. 5: 551. doi:10.3389/fimmu.2014.00551.
33. Notley, C. A., and M. R. Ehrenstein. 2010. The yin and yang of regulatory T cells and inflammation in RA. Nat. Rev. Rheumatol. 6: 572-577.
34. Pan, Z. J., C. G. Horton, C. Lawrence, and A. D. Farris. 2016. Plasmacytoid dendritic cells and type 1 IFN promote peripheral expansion of Foxp3 regulatory T cells specific for the ubiquitous RNA-binding nuclear antigen La/SS-B. Clin. Exp. Immunol. doi:10.1111/cei.12817.
35. Chen, W., X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar. 2008. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181: 5396-5404.
36. Mezrich, J. D., J. H. Fechner, X. Zhang, B. P. Johnson, W. J. Burlingham, and C. A. Bradfield. 2010. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185: 3190-3198.
37. Hadaschik, E. N., and A. H. Enk. 2015. TGF-β1-induced regulatory T cells. Hum. Immunol. 76: 561-564.
38. Belladonna, M. L., U. Grohmann, P. Guidetti, C. Volpi, R. Bianchi, M. C. Fioretti, R. Schwarcz, F. Fallarino, and P. Puccetti. 2006. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177: 130-137.
39. + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA 105: 10113-10118.
40. Fallarino, F., U. Grohmann, K. W. Hwang, C. Orabona, C. Vacca, R. Bianchi, M. L. Belladonna, M. C. Fioretti, M. L. Alegre, and P. Puccetti. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4: 1206-1212.
41. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101.
42. Cribbs, A. P., A. Kennedy, H. Penn, J. E. Read, P. Amjadi, P. Green, K. Syed, S. W. Manka, F. M. Brennan, B. Gregory, and R. O. Williams. 2014. Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway. Arthritis Rheumatol. 66: 2344-2354.
43. Sleijfer, S., M. Bannink, A. R. Van Gool, W. H. Kruit, and G. Stoter. 2005. Side effects of interferon-alpha therapy. Pharm. World Sci. 27: 423-431.
44. Bessede, A., M. Gargaro, M. T. Pallotta, D. Matino, G. Servillo, C. Brunacci, S. Bicciato, E. M. Mazza, A. Macchiarulo, C. Vacca, et al. 2014. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511: 184-190.